These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Streptomycin-starved Mycobacterium tuberculosis 18b, a drug discovery tool for latent tuberculosis. Zhang M; Sala C; Hartkoorn RC; Dhar N; Mendoza-Losana A; Cole ST Antimicrob Agents Chemother; 2012 Nov; 56(11):5782-9. PubMed ID: 22926567 [TBL] [Abstract][Full Text] [Related]
9. Development of rifapentine susceptibility tests for Mycobacterium tuberculosis. Heifets L; Sanchez T; Vanderkolk J; Pham V Antimicrob Agents Chemother; 1999 Jan; 43(1):25-8. PubMed ID: 9869560 [TBL] [Abstract][Full Text] [Related]
10. Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages. Mor N; Simon B; Mezo N; Heifets L Antimicrob Agents Chemother; 1995 Sep; 39(9):2073-7. PubMed ID: 8540718 [TBL] [Abstract][Full Text] [Related]
11. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. Rosenthal IM; Williams K; Tyagi S; Peloquin CA; Vernon AA; Bishai WR; Grosset JH; Nuermberger EL Am J Respir Crit Care Med; 2006 Jul; 174(1):94-101. PubMed ID: 16574936 [TBL] [Abstract][Full Text] [Related]
12. Moxifloxacin and gatifloxacin in an acid model of persistent Mycobacterium tuberculosis. Kubendiran G; Paramasivan CN; Sulochana S; Mitchison DA J Chemother; 2006 Dec; 18(6):617-23. PubMed ID: 17267339 [TBL] [Abstract][Full Text] [Related]
13. [In vitro study on cross resistance of rifampin and rifapentine for Mycobacterium tuberculosis]. Duanmu HJ; Liu YH; Jiang GL; Wang SM; Fu YH Zhonghua Jie He He Hu Xi Za Zhi; 2005 Mar; 28(3):192-4. PubMed ID: 15854417 [TBL] [Abstract][Full Text] [Related]
14. Activity of DNA-targeted C8-linked pyrrolobenzodiazepine-heterocyclic polyamide conjugates against aerobically and hypoxically grown Mycobacterium tuberculosis under acidic and neutral conditions. Iacobino A; Giannoni F; Fattorini L; Brucoli F J Antibiot (Tokyo); 2018 Sep; 71(9):831-834. PubMed ID: 29795520 [TBL] [Abstract][Full Text] [Related]
15. Activity in vitro of rifabutin, FCE 22807, rifapentine, and rifampin against Mycobacterium microti and M. tuberculosis and their penetration into mouse peritoneal macrophages. Dhillon J; Mitchison DA Am Rev Respir Dis; 1992 Jan; 145(1):212-4. PubMed ID: 1309967 [TBL] [Abstract][Full Text] [Related]
16. Activity of drug combinations against dormant Mycobacterium tuberculosis. Filippini P; Iona E; Piccaro G; Peyron P; Neyrolles O; Fattorini L Antimicrob Agents Chemother; 2010 Jun; 54(6):2712-5. PubMed ID: 20350948 [TBL] [Abstract][Full Text] [Related]
17. In vitro evaluation of novel inhalable dry powders consisting of thioridazine and rifapentine for rapid tuberculosis treatment. Parumasivam T; Chan JG; Pang A; Quan DH; Triccas JA; Britton WJ; Chan HK Eur J Pharm Biopharm; 2016 Oct; 107():205-14. PubMed ID: 27422209 [TBL] [Abstract][Full Text] [Related]
18. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Tasneen R; Li SY; Peloquin CA; Taylor D; Williams KN; Andries K; Mdluli KE; Nuermberger EL Antimicrob Agents Chemother; 2011 Dec; 55(12):5485-92. PubMed ID: 21930883 [TBL] [Abstract][Full Text] [Related]
19. In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis. Lechartier B; Hartkoorn RC; Cole ST Antimicrob Agents Chemother; 2012 Nov; 56(11):5790-3. PubMed ID: 22926573 [TBL] [Abstract][Full Text] [Related]
20. Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy. de Knegt GJ; ten Kate MT; van Soolingen D; Aarnoutse R; Boeree MJ; Bakker-Woudenberg IA; de Steenwinkel JE Tuberculosis (Edinb); 2014 Dec; 94(6):701-7. PubMed ID: 25621361 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]